FDA asks ViroPharma to conduct additional trials on HAE drug Cinryze

ViroPharma

Before it gives a decision to ViroPharma's supplemental biologics license application, the Food and Drug Administration has asked the company to conduct an additional clinical study of its experimental angiodema drug Cinryze - the FDA told ViroPharma on Thursday that the placebo-controlled study submitted to support the application "lacked robustness."

The Cinryze drug manufactured by the Exton, Pennsylvannia-based biotechnology company is already approved for use in prevention of hereditary angioedema attacks. The company is now seeking Cinryze's approval as a treatment for hereditary angioedema (HAE) - a life-threatening condition leads to swelling in different body parts like the hands, feet, face and throat.

With Cinryze being in the market only for a few months as a preventive medication for HAE attacks, analyst Steve Brozak of WBB Securities, said that till FDA approves a drug for use in severe attacks of a specified disease, it does not send clear signals about the effectiveness of the drug to the physicians.

On the question of conducting the FDA-recommended additional trial with regard to Cinryze, ViroPharma's CEO Vincent Milano told Reuters that the company was yet to take a decision towards this end.

However, Maxim Group analyst Yale Jen, saying that ViroPharma would likely decide against the additional trials, added: "Why work on something that potentially could have absolutely no reward or very low reward?"

Latest News

Cruise Companies to Balk US-Canada Pollution Plan
California Governor's Race To Make Records in Terms of Money
Serving Whale Meat Shuts Down Santa Monica Sushi Restaurant
Captiva sports utility vehicle Recall
John Lipsky Says Advanced economies face High Debt Challenges
Kirstie Alley’s ‘Big’ New Show for Her Weight-Loss Plan
China Cautions U.S Against its Trade Policies
Rosie O'Donnell Comeback
Volcanic Eruption Leads to Evacuations in Iceland
SABMiller
Kentucky Remains No. 1
Lady Gaga Files a Counter Lawsuit